Kopp Family Office Trims $3.5 Million Worth of Viridian Therapeutics Stake -- What Investors Should Know
Viridian Therapeutics is a clinical-stage biotech awaiting an FDA decision on its lead thyroid eye disease therapy.
Open original sourceLoading market dashboard